{"id":414022,"date":"2021-01-13T08:33:09","date_gmt":"2021-01-13T13:33:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=414022"},"modified":"2021-01-13T08:33:09","modified_gmt":"2021-01-13T13:33:09","slug":"investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/","title":{"rendered":"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Jan.  13, 2021  (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zf1vJzYVU4VdLQ_j-3CO-sUVutyaJmjzdkN_Dbq9By_1xs5bncEQLIQ5iAflB50MT7FsANAAElccsq_9TdT6-sZQfElaY_diQ4w_P_c-kRblaoSdrvgZ06vrYt76xae4PmJuKm8nUKR_U9n3VoB6lNqs6vDklPmfJB7x1S3jWIkqpjIXVcplStb_JYcJ7tyj\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)<\/a>, a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announces it has selected the corporate communications expertise of the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=heUN6iGF7GdyBG5aSY6Mu4KEErpwi_cBdsvbQV3rDX5gUbTFS9z60NvlhMusFantg2Y5kvpEaLyu3pP9j2rYAUlTubOIZPVgq4Ak7sG6pOA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorBrandNetwork<\/a> (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities.<\/p>\n<p align=\"justify\">Imagin Medical\u2019s first product is the i\/Blue Imaging\u2122 System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons\u2019 ability to visualize and remove cancer cells. The i\/Blue System combines both white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in real-time, without the necessity to switch back and forth between the two images. Unlike other methods available on the market today, the system is external to the body and can attach to almost any endoscope model currently in use, allowing hospitals to adopt the technology without the need to purchase new equipment.<\/p>\n<p align=\"justify\">As part of the Client Partner relationship with Imagin Medical, IBN will leverage its investor-based distribution network of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BgyhvkNeIOEnc44nhFvnCOv0GeRgHwIHNB6aAlv-Z1kQ86hqNUyMOWUsHMrjZ1SdV2VPnqERxgK4i3g1p6dK-UAd_TzQDh-9f7VkYx_9QBDw1nQ3_N0EbP71SpGPFwZLYVmmDigP-ShxkKMMCveJ_wrwifIeF6Vww1F592dzd8zbHt_ch4EjusMI75pvWag_z9HiSKxtfTep-fhdLR9Umg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">5,000+ key syndication outlets<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OP94Wbj8-IrIfsUKQ8OKAqNA9tGngBm6vYNeGa_1BSDOEzx50x7Vm8zpq-TnKHVgpvEv9PPRIGUPEohrgdCTgJu_YFuSUZDUHHh0W4qLX061pne5pweWu7FoeOwsjvzM\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">various newsletters<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hh0HmpgYJmVevLBpaNtzA3VkVXpm2tEilIW4JqbX6cElCmOq930w5Er1FrESaRIh--nGjWq3iKuAtrYXWYEsHQ2RFQsKXHpkIRjhCDonihlfoP-NNK1lQlCDcV0uM101a2KYEtFd-nziNpFPkuZjvQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">social media channels<\/a>, wire services via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=heUN6iGF7GdyBG5aSY6Mu_a41QSAC3xgSeCrI5oYt0Ps5hzQYz8I8XMF0bOC6sqBlR2C4ZpH1ZJv1gp2shW-IA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorWire<\/a>, blogs and other outreach tools to generate greater awareness for <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zf1vJzYVU4VdLQ_j-3CO-jDnMFmDeYmu55_Xy1mOFzmEiE62zmT7ModEGOVi1IlKLJ2yAvq5E3BNirG9JApLkJHS56wIkJANpeQjZZGOB1OByl8HctGsLhftS2S2oXwiEDI4icSW4IK9oqkDFWHNiA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Imagin Medical<\/a>.<\/p>\n<p align=\"justify\">\u201cWe are pleased to engage IBN to maximize our communication with existing and potential shareholders while refining our overall messaging and outreach,\u201d states Jim Hutchens, President &amp; CEO of Imagin Medical.<\/p>\n<p align=\"justify\">With 15+ years of experience helping <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6_UepAe9IrqXpQ38lnWwfCZuLd0pLGSsxjSavSMCiseXyNhFKmjRLN5ugefwx_47MRrKtlv8lyKgSY7VV_lOsVLVU9j0BtFP9eCr3_UUgpmLyQ7lmXGK5gOadvV8r65u\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">500+ client partners<\/a> improve communications within the investment community, as well as a sizable family of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3bJkVFSRiKF8il1QRPD92FGDWUhZbLVcmfi8dc6EfvvW4r6ELbZkRAAz9MGBt-u8dQfUNSS3iTUtlZ-spVweJ8j77gb-9sSyIiErhTshe2QwHSnipNjzZgTcHZynv549\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">50<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8IhdilsGCTeXPfpkt5TFynC37eSAQthP15aqas-e9TjR0osDa-okOAH9x7VR69r7qKIG89j7dI4J8kkOtjJzbR5192x8rhKE8xaj7q0-EuRcsgFJE_REkup2Vsaj54468dGy7gYXVct_Y4IqQvtv1g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">+ trusted brands<\/a>, IBN has amassed a collective audience that includes <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SzlPbGPXmvGr9IWgGkzToWuoDaUGrZZK8SAN-Kn9EvRmdqG4dyReoC0LEESX2sIbBAVhWVwqAj_G-EUcx70q84Ni6zHhkRZD6yH3yg7OVkfDN7uZnOSXPOeOlZCJ36sFsWZIP0gj0rqyFd7Zw1OvCZ04LQkkBNhANlsuu2ruCSU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">millions of social media followers<\/a>. IBN is uniquely positioned to provide Imagin Medical with the solutions needed to reach a wide audience that includes investors, consumers, journalists and the general public.<\/p>\n<p align=\"justify\">\u201cBladder cancer is the sixth most prevalent form of cancer in the United States, with new cases in 2020 estimated to have accounted for roughly 4.5% of all new cancers diagnosed. Additionally, it has one of the highest recurrence rates among all forms of cancer,\u201d states Chris Johnson, Director of Client Solutions for IBN. \u201cImagin Medical is committed to addressing this market need through its i\/Blue Imaging System, which has been shown to enhance accuracy of detection and removal of cancer cells, potentially lowering recurrence rates. We\u2019re excited to customize our comprehensive suite of corporate communications solutions for Imagin Medical as it continues to promote adoption of this potentially game changing approach to imaging.\u201d<\/p>\n<p align=\"justify\">To learn more about Imagin Medical, visit the company&#8217;s corporate newsroom profile at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=D7R_9ZLT2gu3KxPwPhTgWqhhTB-geQq2kolIBTqsdGcFzZf91O0NPuizLAbRAizbaMq5nLNh8aZyPDsU7rwgpQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.IBN.fm\/IMEXF<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Imagin Medical Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i\/Blue\u2122 Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company&#8217;s initial focus is bladder cancer. For more information, visit the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NTRSqzWncF9aUzKqXjJUy4xXZaHmlepblwg4BaAqQVXWH5_jWsUG2q5uV1TZNWXuqp6A_0CZneaska3sM3pQ6SUdzJCkaq6a2R9j6QoYG8Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.imaginmedical.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About InvestorBrandNetwork <\/strong>\n      <\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=heUN6iGF7GdyBG5aSY6Mu6ACigjBcZ4IZzQuyDS8TJdBAe6r7dE8wUnbAvh6c_-IveEA0kwco_0Wk-ORZW5WgobEO3FXdMT_syg80rbboU-6CLxhchvoWjHXbpRjtrX6\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorBrandNetwork<\/a> (\u201cIBN\u201d) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of Client Partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.<\/p>\n<p align=\"justify\">Through <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z7KIuTgsM5xamGsQPxUKaWPzPVmm2k9sKK4KaoeQiKbTK3ArVdAO4LcLNH-T_jNA0PBliWAc6Cy_MiYw0NUxcAkIhhnnuWvPvIwJZ3aM4VU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NetworkNewsWire<\/a> (\u201cNNW\u201d) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=heUN6iGF7GdyBG5aSY6Mu8fba_WN5xLUo___smDYXs6FUGp6JbORDceVwqJ59JUgnSqfz5_gq04GaQuqpLWKN1G-coKlkdy2zaJZr78H8Dw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorWire<\/a> to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.<\/p>\n<p align=\"justify\">For more information on IBN, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=idmvYpN_GNNygSyrJobhd86EsX6Cruv7iPLufr7-tEr-HCLJAQEj45Bn0j86NYQwHpCTrGY73TJjeDIJxbKZHI8XTR3UZe46TtWgftD7qzds_BwT9YJk5axVFVimTDBey5t2lrHPJEYEui5EMsJ08w==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.InvestorBrandNetwork.com<\/a>.<\/p>\n<p align=\"justify\">Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Hx07EGeuCaXbxnbsN-_I6Rtlpqa_FsyXv2_eKUHme4mJ2AHaj0K73xpTAs8SeKPWaHOE3JUa0HRdXIw_DNsX7W86Dp1JM1JkTaW59xIh66dop3lG9bSqv34MLl2KyQYS\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/IBN.fm\/Disclaimer<\/a><\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company&#8217;s SEC filings. These risks and uncertainties could cause the company&#8217;s actual results to differ materially from those indicated in the forward-looking statements.<\/p>\n<p align=\"justify\">\n        <strong>Corporate Communications<\/strong>\n      <\/p>\n<p>InvestorBrandNetwork (IBN)<br \/>Los Angeles, California<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=c0gh2QmO1WOuyT4pSXnj8ZmSrRjvb5FGqk0muzSV0ktX42lUejz0OzwD2KXSV95JSJ_2Gu-UZggHxOrkj5TNJ7qwImLgs2KoOBV-WFJLfzZTqh9yqUJJtcFosb7MWxzk\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.InvestorBrandNetwork.com<\/a><br \/>310.299.1717 Office<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L_RjZXWEYSPy5ptGTcy_IyicLAmsg7EnGY1QffR3i9p3Qgbh0Vv-ieYRWMZKTm7zoUW4-ocCp8ikj5X7jbINVm4R4pUazPDC65_GJLQdxI4Lmh6Tr6EaHPhd1qk0OBW1\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Editor@InvestorBrandNetwork.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/603f5a91-a37c-4fe5-a222-ebc9efe67bf7\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announces it has selected the corporate communications expertise of the InvestorBrandNetwork (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities. Imagin Medical\u2019s first product is the i\/Blue Imaging\u2122 System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons\u2019 ability to visualize and remove cancer cells. The i\/Blue System combines both white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-414022","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announces it has selected the corporate communications expertise of the InvestorBrandNetwork (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities. Imagin Medical\u2019s first product is the i\/Blue Imaging\u2122 System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons\u2019 ability to visualize and remove cancer cells. The i\/Blue System combines both white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in &hellip; Continue reading &quot;InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-13T13:33:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)\",\"datePublished\":\"2021-01-13T13:33:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/\"},\"wordCount\":849,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/\",\"name\":\"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=\",\"datePublished\":\"2021-01-13T13:33:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/","og_locale":"en_US","og_type":"article","og_title":"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Market Newsdesk","og_description":"NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2013 Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announces it has selected the corporate communications expertise of the InvestorBrandNetwork (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities. Imagin Medical\u2019s first product is the i\/Blue Imaging\u2122 System, based on advanced optics and light sensors and employing patented ultrasensitive imaging technology. Imagin Medical believes the system can significantly improve surgeons\u2019 ability to visualize and remove cancer cells. The i\/Blue System combines both white and blue light with an FDA-approved imaging agent and simultaneously displays side-by-side images in &hellip; Continue reading \"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-13T13:33:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)","datePublished":"2021-01-13T13:33:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/"},"wordCount":849,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/","name":"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=","datePublished":"2021-01-13T13:33:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMjQ4NiMzOTA5NjQyIzIwODg3OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-coverage-initiated-for-imagin-medical-inc-cse-ime-otcqb-imexf\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=414022"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/414022\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=414022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=414022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=414022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}